Dual-purpose linker for alpha helix stabilization and imaging agent conjugation to glucagon-like peptide-1 receptor ligands.
Bioconjug Chem · 2015
Last updated 2026-05-28Researchers designed a new chemical linker to stabilize and label peptides that target the GLP-1 receptor, including exendin and GLP-1. The stabilized peptides showed increased structure stability, better resistance to breakdown, and maintained or improved their ability to bind to the receptor. In animal tests, the labeled peptides effectively targeted their intended sites, suggesting potential use for imaging beta cells in diabetes studies.
AI summary of the abstract below.
| Journal | Bioconjug Chem, 2015 |
|---|---|
| Citations | 18 |
| Relative citation ratio | 0.71 |
| NIH percentile | 39 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
Peptides display many characteristics of efficient imaging agents such as rapid targeting, fast background clearance, and low non-specific cellular uptake. However, poor stability, low affinity, and loss of binding after labeling often preclude their use in vivo. Using glucagon-like peptide-1 receptor (GLP-1R) ligands exendin and GLP-1 as a model system, we designed a novel α-helix-stabilizing linker to simultaneously address these limitations. The stabilized and labeled peptides showed an increase in helicity, improved protease resistance, negligible loss or an improvement in binding affinity, and excellent in vivo targeting. The ease of incorporating azidohomoalanine in peptides and efficient reaction with the dialkyne linker enable this technique to potentially be used as a general method for labeling α helices. This strategy should be useful for imaging beta cells in diabetes research and in developing and testing other peptide targeting agents.
Verbatim abstract via PubMed 25594741 ↗